HRMY vs JAZZ
HRMY: Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor antagonist for narcolepsy, with an expanding pipeline in rare epilepsy and sleep disorders. JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments.
Side-by-side fundamentals
| Metric | HRMY | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.86 | $250.41 | |
| Market cap as of 2026-07-23 | $2.0B | $16.0B | |
| P/E as of 2026-07-23 | 13.86 | 543.13 | HRMY lower |
| PEG as of 2026-07-23 | 0.20 | 58.02 | HRMY lower |
| Net margin as of 2026-07-23 | +16.2% | +0.7% | HRMY higher |
| Gross margin as of 2026-07-23 | +76.5% | +88.0% | JAZZ higher |
| Operating margin as of 2026-07-23 | +21.1% | -0.8% | HRMY higher |
| ROE as of 2026-07-23 | +17.2% | +0.7% | HRMY higher |
| ROA as of 2026-07-23 | +12.0% | +0.3% | HRMY higher |
| Debt / equity as of 2026-07-23 | 0.17 | 1.18 | HRMY lower |
| Revenue growth (YoY) as of 2026-07-23 | +20.7% | +9.2% | HRMY higher |
| Revenue CAGR (3y) SEC XBRL | +25.6% | +5.3% | HRMY higher |
| Beta as of 2026-07-23 | 0.91 | 0.37 | |
| 1-year return as of 2026-07-22 close | +4.5% | +125.7% | JAZZ higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.